MSI-high Endometrial Cancer
Showing 1 - 25 of >10,000
Endometrial Cancer Trial in United States (Intensity modulated radiation therapy (IMRT), Dostarlimab)
Recruiting
- Endometrial Cancer
- Intensity modulated radiation therapy (IMRT)
- Dostarlimab
-
Basking Ridge, New Jersey
- +6 more
Jul 5, 2022
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High Trial in United States
Recruiting
- Advanced or Metastatic Solid Tumors
- +11 more
-
Tucson, Arizona
- +11 more
Dec 2, 2022
MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma Trial in Spain (Spartalizumab)
Active, not recruiting
- MSI-H Colorectal Cancer
- +30 more
-
Badalona, Barcelona, Spain
- +9 more
Oct 24, 2022
Cancer Screening Trial (transvaginal ultrasound and microscale endometrial sampling biopsy)
Not yet recruiting
- Cancer Screening
- transvaginal ultrasound and microscale endometrial sampling biopsy
- (no location specified)
Nov 5, 2023
Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab
Not yet recruiting
- Colorectal Cancer
- +3 more
- Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
-
ZhengZhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jun 18, 2023
Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant
Not yet recruiting
- Multiple Cancer
- Colorectal Cancer
- MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
- All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
- (no location specified)
Aug 20, 2023
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and
Completed
- Cervical Cancer
- +16 more
- INCAGN02385
-
Los Angeles, California
- +3 more
Oct 28, 2020
Neoadjuvant Envafolimab in Resectable and Locally Advanced
Not yet recruiting
- Locally Advanced Rectal Carcinoma
- MSI-High
- (no location specified)
Dec 9, 2022
Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)
Not yet recruiting
- Adenocarcinoma - GEJ
- Gastric Adenocarcinoma
- (no location specified)
Sep 26, 2023
MSI-H Trial in Guangzhou (IBI310, Radical surgery, Sintilimab)
Not yet recruiting
- MSI-H
- IBI310
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
May 26, 2023
Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))
Active, not recruiting
- Colorectal Cancer
- IBI310 (anti-CTLA-4 antibody)
- Sintilimab(anti-PD-1 antibody)
-
Beijing, ChinaBeijing cancer hospital
Sep 15, 2022
Endometrial Cancer Trial in Chapel Hill (HIIT exercise)
Recruiting
- Endometrial Cancer
- HIIT exercise
-
Chapel Hill, North CarolinaUNC Lineberger Comprehensive Cancer Center
Feb 2, 2023
Gastric Cancer, Microsatellite Instability Trial in Milan (Durvalumab, Tremelimumab)
Recruiting
- Gastric Cancer
- Microsatellite Instability
-
Milan, ItalyFondazione IRCCS Istituto Nazionale dei Tumori di Milano
Aug 3, 2022
Endometrial Cancer, Serous Adenocarcinoma, Uterine Tumor Trial (Niraparib oral capsule)
Not yet recruiting
- Endometrial Cancer
- +2 more
- Niraparib oral capsule
- (no location specified)
Oct 31, 2022
Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)
Not yet recruiting
- Colorectal Cancer Stage IV
- +2 more
- (no location specified)
Jun 19, 2022
Endometrial Cancer Trial in Oklahoma City (Pembrolizumab, Vaginal cuff brachytherapy (VCB), Paclitaxel)
Recruiting
- Endometrial Cancer
- Pembrolizumab
- +3 more
-
Oklahoma City, OklahomaStephenson Cancer Center
Jan 9, 2023
Colorectal Carcinoma Trial in Guangzhou (Sintilimab, Oxaliplatin, capecitabine)
Recruiting
- Colorectal Carcinoma
- Sintilimab
- +2 more
-
Guangzhou, ChinaSun Yat-sen University
Dec 29, 2022
Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)
Completed
- Recurrent/Metastatic Gastric Cancer
- Nivolumab, Paclitaxel
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Sep 9, 2022
Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in Guangzhou (Neoadjuvant
Recruiting
- Colorectal Cancer
- +3 more
- Neoadjuvant therapy with PD-L1 inhibitor
-
Guangzhou, Guangdong, Chinathe Third Affiliated Hospital of Sun Yat-Sen University
May 10, 2022
POLE Exonuclease Mutant Colon Cancer, Microsatellite Instability, Stage III Colon Cancer Trial in Sutton (Avelumab)
Terminated
- POLE Exonuclease Mutant Colon Cancer
- +2 more
-
Sutton, Surrey, United KingdomRoyal Marsden NHS Foundation Trust
Oct 5, 2022
MSI-H/dMMR Solid Tumor Trial in Guangzhou (AK104)
Terminated
- MSI-H/dMMR Solid Tumor
-
Guangzhou, Guangdong, ChinaSun Yat-Sen University Cancer Center
Oct 17, 2022
Metastatic Colorectal Cancer Trial in China (HX008, Investigator's Choice Chemotherapy)
Not yet recruiting
- Metastatic Colorectal Cancer
- HX008
- Investigator's Choice Chemotherapy
-
Hefei, Anhui, China
- +9 more
Dec 8, 2022